A share price of Travere Therapeutics Inc [TVTX] is currently trading at $18.33, up 3.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TVTX shares have gain 22.86% over the last week, with a monthly amount drifted -11.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo upgraded its rating to Overweight on October 21, 2024, and elevated its price target to $27. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Guggenheim upgraded its rating to a Buy but stick to its price target of $25 on September 09, 2024. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to Buy for this stock on December 05, 2023, and upped its price target to $10. In a note dated November 20, 2023, Citigroup initiated an Neutral rating and provided a target price of $7 on this stock.
Travere Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.12 and $25.29. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $18.33 at the most recent close of the market. An investor can expect a potential return of 80.03% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Trailing Twelve Months sales for Travere Therapeutics Inc [NASDAQ:TVTX] were 233.18M which represents 65.98% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -1.38%, Pretax Profit Margin comes in at -1.37%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -10.91 and Total Capital is -0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.60 points at the first support level, and at 16.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.76, and for the 2nd resistance point, it is at 19.18.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Travere Therapeutics Inc [NASDAQ:TVTX] is 2.08. As well, the Quick Ratio is 2.04, while the Cash Ratio is 0.29. Considering the valuation of this stock, the price to sales ratio is 6.98, the price to book ratio is 27.13.
Transactions by insiders
Recent insider trading involved Cline Christopher R., CHIEF FINANCIAL OFFICER, that happened on Apr 11 ’25 when 48.0 shares were sold. Officer, Christopher Cline completed a deal on Apr 11 ’25 to buy 48.0 shares. Meanwhile, SENIOR VICE PRESIDENT, R&D ROTE WILLIAM E. sold 5200.0 shares on Feb 12 ’25.
